Navigation Links
FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility
Date:6/29/2011

going commitment to patients, Dendreon will conduct a registry of approximately 1500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full prescribing information or call 1-877-336-3736.

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in men in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 240,890 new cases and approximately 33,720 men expected to die from the disease in 2011.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response.  Dendreon's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and has manufacturing facilities in New Jersey, Georgia and California. Dendreon is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://w
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves New Device to Treat Brain Aneurysms
2. European Commission Approves DuPont Tender Offer to Acquire Danisco
3. New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test
4. European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
5. FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy
6. European Union Approves Maize with Herculex® I/Herculex® RW and Herculex® RW/ Herculex® I/Roundup Ready® Corn 2 Trait Stacks for Import, Food, Feed & Processing
7. FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests
8. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
9. FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
10. European Union Approves Corn Stack with Herculex RW and Roundup Ready 2 Traits for Food, Feed, Import and Processing
11. EU Committee Approves New Food Applications for Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... yields to disease risks, the biological characteristics people care ... as for heightthe textbook example of a complex traitattributes ... by multiple genetic and environmental influences, making it challenging ... genes, geneticists typically mate two individuals that differ in ... mouseand then study their descendents, looking for genes that ...
(Date:9/19/2014)... Biotech companies make announcements illustrating ... systems and advanced Laboratory Instrumentation. Companies in focus today ... BDX ), Thermo Fisher Scientific Inc. (NYSE: ... RGDO ), Sangamo Biosciences Inc. (NASDAQ: SGMO ... BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Cereal ... food industries will gather October 5–8, 2014, for ... Rhode Island Convention Center in Providence, Rhode Island. ... the work of food scientists, chemists, microbiologists, nutritionists, ... and food production management. To date, 1,000 attendees ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... , , LONDON and ... Silence Therapeutics plc (AIM: SLN) today announced that Philip Haworth ... update at the 12th Annual BIO CEO & Investor Conference.  The conference ... in New York City . , Silence,s presentation will take place ...
... OAK RIDGE, Tenn., Feb. 4, 2010 -- Four Oak ... that will receive five-year research grants as part of ... The $85 million program, funded under the American ... Science, is designed to support exceptional researchers during the ...
... , Feb. 4 A comprehensive study of ... community oncology practices revealed that Medicare covers only 56% of ... room services to seniors with cancer. The remaining costs -- ... and follow-up care planning -- are not reimbursed by Medicare, ...
Cached Biology Technology:Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference 2Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference 34 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 2Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 3Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 4
(Date:9/18/2014)... new GSA Bulletin study uses tree rings ... and Chaco Wash in northern New Mexico, USA. By ... and willow, investigators were able to precisely date arroyo ... combined this data with aerial imagery, LiDAR, longitudinal profiles, ... arroyos. , Arroyos are deep, oversized channels that have ...
(Date:9/18/2014)... and the Quebec government have discovered microplastics (in ... of Fisheries and Aquatic Sciences . , The ... industrial cleansers, to which they are commonly added ... buoyancy, they may readily pass through sewage treatment ... the world,s oceans, but have only recently been ...
(Date:9/18/2014)... DNA, tiny strands of nucleic acid that contain instructions ... genetic data, our DNA is copied into RNA molecules, ... tasks in our cells. , Several years ago, ... all other known RNAs, this molecule is circular, and ... little has been known about how they are produced. ...
Breaking Biology News(10 mins):Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... tested two candidate vaccines that may eventually be used ... findings are published in the December 15 issue of ... Barney S. Graham, MD, PhD, and colleagues from the ... Maryland, the Fred Hutchinson Cancer Research Center in Seattle, ...
... the University of Rochester may have answered one of ... neurons, which are responsible for our crystal-clear thoughts, seem ... November issue of Nature Neuroscience, the Rochester study shows ... signals to represent the ambiguities of the real world--and ...
... may be fueling the spread of HIV in areas of ... two diseases, while HIV may be playing a role in ... according to a new study by researchers at Fred Hutchinson ... findings, published in the Dec. 8 issue of Science, found ...
Cached Biology News:Progress made in HIV vaccine development 2Mysterious 'neural noise' actually primes brain for peak performance 2Mysterious 'neural noise' actually primes brain for peak performance 3Malaria may fuel spread of HIV in sub-Saharan Africa 2
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Desmosomal Protein Immunogen: Full length, native protein purified from human epidermal keratins. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Biology Products: